Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001066607 | SCV001231622 | benign | Tuberous sclerosis 2 | 2023-09-08 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001788415 | SCV002031107 | uncertain significance | not provided | 2022-10-11 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Genome- |
RCV001066607 | SCV002040901 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002348463 | SCV002646468 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-15 | criteria provided, single submitter | clinical testing | The p.R1793W variant (also known as c.5377C>T), located in coding exon 41 of the TSC2 gene, results from a C to T substitution at nucleotide position 5377. The arginine at codon 1793 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |